PHASE I STUDY OF 2- OR 3-WEEK DOSING OF TELISOTUZUMAB VEDOTIN, AN ANTIBODY–DRUG CONJUGATE TARGETING C-MET, MONOTHERAPY IN PATIENTS WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA